BackLotus Pharmaceuticals Overview
Lotus Pharmaceuticals, Inc.

Lotus Pharmaceuticals P/E Ratio

Latest P/E ratio for Lotus Pharmaceuticals: -335.97 — see history and peer comparisons.

Get informed when a big investor buys or sells

+ Follow

P/E Ratio

-335.97

P/E Ratio

-335.97

The P/E ratio compares a company's stock price to its earnings per share. A lower P/E ratio may indicate that the stock is undervalued.

P/E Ratio (Comparison Companies)

Loading

P/E Ratio History

Loading

P/E Ratio Comparison

Loading

Lotus Pharmaceuticals (LTUS) FAQ

The latest P/E ratio for LTUS is -335.97. That is below the sector sector average of 22.75. Investors often review this figure alongside Lotus Pharmaceuticals's historical trend and sector peers before judging valuation or financial health.

Against its sector companies, LTUS currently prints -335.97 for P/E ratio, while the sector average sits near 22.75. That is roughly 1576.7% below the sector mean. Large gaps often invite a closer look at Lotus Pharmaceuticals's growth, margins, and balance sheet.

A P/E ratio of -335.97 for Lotus Pharmaceuticals is not 'good' or 'bad' on its own. Compare it with the peer average (22.75) and with LTUS's multi-year chart on this page. Persistently elevated multiples need growth or quality to justify them; depressed multiples need a catalyst or evidence the business is misunderstood.

After noting LTUS's P/E ratio (-335.97), review year-over-year change, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.

Questions & Answers